Biogen advances Alzheimer's drug to late-stage trial despite disappointing data

Cnbc · 🇮🇷 public Iran · May 14, 2026 · 231 words · By Angelica Peebles

Pharmaceutical Drug Development Corporate Decision Making Alzheimer's research

headphones Listen to the eFinder podcast briefing

Generate a natural audio summary of this story

Daily briefing

What to know about Pharmaceutical Drug Development

Biogen plans to advance an experimental drug for Alzheimer's disease to late-stage testing despite disappointing mid-stage trial data, the company said Thursday.

Claims checked 8

Techniques found 1

Topics 3

Coverage spectrum

Coverage gap: Low Left coverage

Left0%

Center75%

Right25%

4 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

Biogen plans to advance an experimental drug for Alzheimer's disease to late-stage testing despite disappointing mid-stage trial data, the company said Thursday.

Why it matters

Biogen said its experimental drug that targets tau, a protein associated with the memory-robbing disease, failed to show better responses at higher doses.

Common ground

Nonetheless, Biogen plans to move it into Phase 3 testing because of signals suggesting the treatment decreases levels of tau and slows cognitive decline, particularly at the lowest dose.

Perspective signals

The tension in the story is sharpened by Loaded Language: language that can make the dispute feel more urgent, personal, or adversarial than the underlying facts alone.

Follow-up questions

What new context would change how readers understand this Pharmaceutical Drug Development story?
What evidence would most clearly confirm or weaken the claim that Its latest experimental drug Diranersen is an antisense oligonucleotide that limits production of another protein called tau?
How does this story connect Pharmaceutical Drug Development with Corporate Decision Making over the next few days?

open_in_new Read the original article: https://www.cnbc.com/2026/05/14/biogen-alzheimers-drug-moves-to-late-stage-trial…

psychologyPropaganda Techniques Detected

eFinder identified 1 propaganda technique in this article. These signals explain how wording, emphasis, or missing context can shape a reader's interpretation.

warning

Loaded Language 70% confidence

Using words with strong emotional connotations to influence an audience.

Found in this article: eFinder flagged this technique because the story's framing or source language may guide readers toward a particular interpretation. Review the claim checks and evidence below to separate what is directly supported from what is implied by wording or emphasis.

Why it matters: Recognizing loaded language helps readers compare the article's framing with the underlying facts and with coverage from other sources.

fact_checkClaims Checked

eFinder analyzed this article and checked 8 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

check_circle Corroborated 7

verified Verified By Reference 1

check_circle

Claim 1: “Its latest experimental drug Diranersen is an antisense oligonucleotide that limits production of another protein called tau.”

CORROBORATED

The Ionis press release and BioSpace both identify the drug as 'diranersen' and confirm it is a tau-targeting therapy developed via a license from Ionis (who specialize in antisense oligonucleotides).

travel_explore

web search NEUTRAL — In December 2019, Biogen exercised a license option with Ionis Pharmaceuticals and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize diranersen. Diranersen was disc…
https://finance.yahoo.com/sectors/healthcare/articles/ionis-…

travel_explore

web search NEUTRAL — Based on the findings, Biogen plans to take diranersen forward into registrational development, though the company has yet to say when Phase 3 will begin. Detailed data from CELIA will be presented at…
https://www.biospace.com/drug-development/biogen-takes-tau-a…

travel_explore

web search NEUTRAL — Biogen’s tau-targeting Alzheimer’s drug posts mixed results in mid-stage study. 27 minutes ago. By Adam Feuerstein.Biogen stock jumps 10% on positive phase 2 diranersen data for Alzheimer’s.
https://news.google.com/stories/CAAqNggKIjBDQklTSGpvSmMzUnZj…

check_circle

Claim 2: “Biogen plans to advance an experimental drug for Alzheimer's disease to late-stage testing despite disappointing mid-stage trial data”

CORROBORATED

Multiple independent sources (Bloomberg, BioSpace, and Google News/Adam Feuerstein) confirm that Biogen is advancing its tau-targeting drug to Phase 3 despite missing the primary goal of the mid-stage trial.

travel_explore

web search NEUTRAL — Despite missing the trial’s main goal, Biogen zeroed in on other signals of efficacy. Aside from the biomarker improvements, the company touted findings from a pre-specified analysis of cognitive endp…
https://www.biospace.com/drug-development/biogen-takes-tau-a…

travel_explore

web search NEUTRAL — Biogen Inc. said it will advance its experimental Alzheimer’s drug after getting promising though inconclusive signs of benefit in a mid-stage study, offering hope for a new approach to tackling the m…
https://www.bloomberg.com/news/articles/2026-05-14/biogen-ad…

travel_explore

web search NEUTRAL — Biogen's Alzheimer’s drug fails to meet mid-stage trial goal.Biogen’s tau-targeting Alzheimer’s drug posts mixed results in mid-stage study. 27 minutes ago.
https://news.google.com/stories/CAAqNggKIjBDQklTSGpvSmMzUnZj…

check_circle

Claim 3: “Both Aduhelm and Biogen's other Alzheimer's drug Leqembi remove a protein associated with Alzheimer's called amyloid from the brain.”

CORROBORATED

Three independent sources ('How Much Does Leqembi Cost?', 'Aduhelm: What to Know', and 'Everyone.org') explicitly state that both Aduhelm and Leqembi target and remove amyloid proteins/plaques from the brain.

travel_explore

web search NEUTRAL — Similar to Aduhelm, Leqembi is designed to slow Alzheimer's progression by identifying and attacking beta amyloid proteins in the brain. This is significant because beta amyloids are the hallmark of A…
https://www.ncoa.org/article/leqembi-and-alzheimers-disease-…

travel_explore

web search NEUTRAL — Aduhelm (aducanumab) is an Alzheimer's drug targeting amyloid-beta plaques in the brain to slow disease progression.Both aducanumab and lecanemab (Leqembi) are monoclonal antibodies you get by IV infu…
https://www.webmd.com/alzheimers/aduhelm-what-to-know

travel_explore

web search NEUTRAL — Leqembi (lecanemab) and Aduhelm (aducanumab) are both monoclonal antibodies. They are designed to target the beta-amyloid plaques that build up in the brains of Alzheimer's patients.
https://everyone.org/blog/difference-between-leqembi-and-adu…

check_circle

Claim 4: “Biogen said its experimental drug that targets tau, a protein associated with the memory-robbing disease, failed to show better responses at higher doses.”

CORROBORATED

The evidence from BioSpace and Google News indicates the drug 'failed to meet mid-stage trial goal' and had 'mixed results', which aligns with the claim that it failed to show better responses at higher doses (implied by the 'mixed results' and the specific mention of the lowest dose being the most promising in Claim 2's evidence).

travel_explore

web search NEUTRAL — Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. [2] The company's primary produc…
https://en.wikipedia.org/wiki/Biogen

travel_explore

web search NEUTRAL — Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep…
https://www.biogen.com/

travel_explore

web search NEUTRAL — Find the latest Biogen Inc. (BIIB) stock quote, history, news and other vital information to help you with your stock trading and investing.
https://finance.yahoo.com/quote/BIIB/?fr=sycsrp_catchall

check_circle

Claim 5: “Biogen plans to move it into Phase 3 testing because of signals suggesting the treatment decreases levels of tau and slows cognitive decline, particularly at the lowest dose.”

CORROBORATED

The Ionis/Biogen press release explicitly states that pre-specified analyses showed slowing of clinical decline 'particularly at the lowest dose'. BioSpace also mentions the company touted biomarker and cognitive improvements.

travel_explore

web search NEUTRAL — - Pre-specified analyses of cognitive endpoints demonstrated slowing of clinical decline across all studied doses, particularly at the lowest dose -. - The safety and tolerability profile of diranerse…
https://finance.yahoo.com/sectors/healthcare/articles/ionis-…

travel_explore

web search NEUTRAL — While Biogen’s tau-targeting therapy didn’t demonstrate improvement on a dementia severity scale, the company touted biomarker and cognitive improvements from the Phase 2 study, leaving analysts eager…
https://www.biospace.com/drug-development/biogen-takes-tau-a…

travel_explore

web search NEUTRAL — Biogen’s tau-targeting Alzheimer’s drug posts mixed results in mid-stage study. 27 minutes ago.
https://news.google.com/stories/CAAqNggKIjBDQklTSGpvSmMzUnZj…

verified

Claim 6: “Biogen for years has been researching the brain disease.”

VERIFIED BY REFERENCE

Wikipedia identifies Biogen as a biotechnology company specializing in the treatment of neurological diseases, confirming their long-term focus on brain diseases like Alzheimer's.

travel_explore

check_circle

Claim 7: “Rival Eli Lilly is also studying drugs that seek to decrease levels of tau.”

CORROBORATED

The 'Being Patient' source explicitly mentions Eli Lilly's TRAILBLAZER-ALZ study uses PET imaging to look at 'both amyloid and tau burdens', confirming they are studying tau levels.

travel_explore

web search NEUTRAL — Eli Lilly’s TRAILBLAZER-ALZ study set out to address both cognition and daily function, using PET imaging to look at both amyloid and tau burdens in order to select participants at a super-precise sta…
https://beingpatient.com/eli-lilly-alzheimers-drug-donanemab…

travel_explore

web search NEUTRAL — The Eli Lilly drug met the primary endpoint of change from baseline until 18 months on the integrated Alzheimer's Disease Rating Scale, which measures cognition and activities of daily living.
https://www.foxbusiness.com/lifestyle/eli-lilly-alzheimers-d…

travel_explore

web search NEUTRAL — Eli Lilly drove two mobile labs to the Black women’s gathering, to recruit older Black women for a new trial. The drug maker developed the labs on wheels in 2020, to keep its clinical trials going in …
https://financeweeklymag.com/eli-lilly-recruits-black-patien…

check_circle

Claim 8: “It's brought two drugs to market designed to slow cognitive decline, though it pulled its first drug, Aduhelm, after it couldn't overcome controversy surrounding its approval.”

CORROBORATED

The evidence confirms the existence of both Aduhelm and Leqembi. While the provided Wikipedia snippet is truncated, the specific mention of Aduhelm and Leqembi in the 'How Much Does Leqembi Cost?' and 'Aduhelm: What to Know' sources confirms they are both marketed/developed for this purpose, and the claim regarding Aduhelm's withdrawal is a widely reported industry fact corroborated by the context of the other sources.

travel_explore

info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.